Cloud Pharmaceuticals:
The In Silico Therapeutics Company

Cloud Pharmaceuticals is changing the way drugs are discovered and developed. The worldwide pharmaceutical industry is in need of new drugs that target smaller market segments, are developed faster, and have novel IP, greater drug safety, efficacy, and affordability. Patent protection is expiring for many "blockbuster" medicines and pharmaceutical companies are losing billions to generic competition. But replacing those patented drugs with another blockbuster is unlikely.

Cloud Pharmaceuticals designs new drugs and drug candidates and accelerates the development process by implementing new, innovative cloud computing technology in place of traditional methods. We manage development of multiple assets through an extensive network of partners. This reduces cost, decreases development time, and creates novel molecules with therapeutic value.

Our drug discovery and development implementation consists of in silico drug design technology called Inverse Design that uses high-performance cloud computing resources, followed by immediate preclinical optimization and rapid development toward Investigational New Drug (IND) and Phase 1. We have a growing pipeline including central nervous system (CNS), cancer, inflammation, lipid metabolism, and rare disease indications, among others.

Science

Cloud Pharmaceuticals uses cloud technology and high-performance computing to efficiently calculate which of all possible molecules will be the best drug candidates. For a specific protein target, we computationally design small molecules and peptides that strongly bind to the target, and have favorable toxicity, synthetability, solubility, and stability properties. We synthesize, assay, develop expression profiles and Pk models, and optimize our drug candidates, and then develop them directly or with partners through IND and the clinic.
Learn more >

Partnering

Cloud Pharmaceuticals is helping transform the pharmaceutical / biotechnology industry to embrace, enable, and afford personalized medicine, niche buster drugs, and rapidly develop blockbusters for difficult targets. We use cutting-edge computing, protein models, systems biology, biomarkers, and a systematic approach to drug discovery. Using a network of visionary pre-clinical and clinical development partners, we are riding a new wave of creative destruction.  We seek partners at all stages of drug development, including early stage, preclinical, IND and Phase 1 and 2.
Learn more >

Pipeline

Cloud Pharmaceuticals is engaged in drug discovery and development programs spanning a wide range of indications including:
  • Autism, Alzheimer's, and other neurodegenerative disorders
  • Cancer, solid tumor and hematologic, including lymphoma, fibrosis, blood cancers, lung cancer, etc.
  • Inflammation, rheumatoid arthritis, sarcopenia
  • Kidney disease
  • Orphan diseases including malaria, Dengue fever, and Chagas disease
  • Metabolic disorders, lipid metabolism, etc.
  • Respiratory diseases and chronic obstructive pulmonary disease (COPD)
Learn more>

News

Events

  • Advances in Drug Delivery
    March 12, 2015
    Cambridge, Mass.
    Speaker: Shahar Keinan, "Data Driven Drug Design: In Silico Optimization of BBB Permeability and Toxicity for Better Drugs" 3/12 at 3:15 pm